33,004 Shares in Organon & Co. (NYSE:OGN) Acquired by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in shares of Organon & Co. (NYSE:OGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 33,004 shares of the company’s stock, valued at approximately $683,000.

A number of other institutional investors have also recently added to or reduced their stakes in OGN. Norges Bank bought a new position in shares of Organon & Co. during the 4th quarter valued at $26,321,000. Coldstream Capital Management Inc. bought a new position in Organon & Co. during the fourth quarter valued at about $237,000. Quest Partners LLC acquired a new stake in shares of Organon & Co. in the fourth quarter worth about $168,000. Franklin Resources Inc. boosted its stake in shares of Organon & Co. by 55.7% during the 4th quarter. Franklin Resources Inc. now owns 180,815 shares of the company’s stock worth $2,607,000 after acquiring an additional 64,683 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Organon & Co. by 92.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,321 shares of the company’s stock valued at $62,000 after acquiring an additional 2,075 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their target price for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Stock Down 3.4 %

Organon & Co. stock opened at $19.49 on Monday. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10. The firm has a fifty day moving average price of $21.00 and a two-hundred day moving average price of $20.11. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of 4.77, a P/E/G ratio of 0.89 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. The firm had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 EPS. As a group, analysts forecast that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were paid a $0.28 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 annualized dividend and a dividend yield of 5.75%. Organon & Co.’s payout ratio is 27.38%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.